Complete Atrioventricular (AV) Block as a Cardiac Complication of Rheumatoid Arthritis: A Rare Case Report
Keywords:
cardiac complication, complete atrioventricular (AV) block, rheumatoid arthritisAbstract
Atrioventricular block (AVB) is a rare complication of rheumatoid arthritis (RA). Complete AVB in people with RA significantly increases cardiovascular morbidity and doubles the mortality risk. We report on a 48-year-old woman presenting with dyspnea and peripheral edema, with symptoms of polyarthritis for 3 years. Physical findings included bradycardia, bilateral rales, and finger deformities consistent with RA. Electrocardiography featured complete AVB, and a thoracic computed tomography scan showed a mosaic appearance with fibrosis, bronchiectasis, and partial atelectasis of the lungs. Further tests showed elevated levels of C-reactive protein, rheumatoid factor, and several inflammatory cytokines. Transient followed by permanent pacemaker placement was performed along with pharmacological treatments, including intravenous (IV) methylprednisolone pulse therapy and IV tocilizumab. Cardiac involvement in RA usually takes the form of pericardial effusion, heart failure, myocarditis, and coronary artery disease. Complete AVB is a rare but important extra-articular involvement in RA that warrants early recognition and treatment with a pacemaker, anti-inflammatory drugs, and disease-modifying antirheumatic drugs.References
Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: Lessons from rheumatoid arthritis. Eur Heart J. 2017;38:1717–27.
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.
Parlindungan F, Hidayat R, Sumariyono S, Koesnoe S. Bone turnover imbalance in rheumatoid arthritis: Relationship between tumor necrosis factor-α and dickkopf-1 with bone turnover markers. J Musculoskelet Res. 2022;25.
World Health Organization. Rheumatoid arthritis [Internet]. World Health Organization. 2023 [cited 2024 Mar 3]. Available from: https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis
Black RJ, Cross M, Haile LM, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e594–610.
Hidayat R, Suryana BPP, Wijaya LKW, et al. Diagnosis dan pengelolaan artritis reumatoid. Jakarta: Indonesian Rheumatology Association; 2021.
Suryana BPP, Hidayat R, Sarmidi S, et al. Characteristics and prevalence of clinical remission of rheumatoid arthritis in a nationwide study from Indonesia. Int J Rheum Dis. 2024;27.
Pandit A, Londhey V, Chawla B, Khedkar U, Sundaram S, Asgaonkar DS. Complete heart block in a case of rheumatoid arthritis. J Assoc Physicians India. 2013;61:836–8.
Ahern M, Lever J V, Cosh J. Complete heart block in rheumatoid arthritis. Ann Rheum Dis. 1983;42:389–97.
Dihi B, Eljazouli H, Bouzerda A, Khatouri A. A complete atrioventricular block revealing rheumatoid arthritis: A case report. SAS J Med. 2022;8:430–2.
Rezuș E, Macovei LA, Burlui AM, Cardoneanu A, Rezuș C. Ischemic heart disease and rheumatoid arthritis—two conditions, the same background. Life. 2021;11:1042.
Villecco AS, De Liberali E, Bianchi FB, Pisi E, Di Patologia I. Antibodies to cardiac conducting tissue and abnormalities of cardiac conduction in rheumatoid arthritis. Clin Exp Immunol. 1983;53:536–40.
Seferović PM, Ristić AD, Maksimović R, et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology. 2006;45:iv39-42.
Rawla P. Cardiac and vascular complications in rheumatoid arthritis. Reumatologia. 2019;57:27–36.
Plastiras SC, Moutsopoulos HM. Arrhythmias and conduction disturbances in autoimmune rheumatic disorders. Arrhythm Electrophysiol Rev. 2021;10:17–25.
Sierra-Galan LM, Bhatia M, Alberto-Delgado AL, et al. Cardiac magnetic resonance in rheumatology to detect cardiac involvement since early and pre-clinical stages of the autoimmune diseases: A narrative review. Front Cardiovasc Med. 2022;9:870200.
Ntusi NAB, Francis JM, Gumedze F, et al. Cardiovascular magnetic resonance characterization of myocardial and vascular function in rheumatoid arthritis patients. Hellenic J Cardiol. 2019;60:28–35.
Kishimoto T. IL-6 from laboratory to bedside. Clin Rev Allergy Immunol. 2005;28:177–86.
Castell J V., Gómez‐lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6. Hepatology. 1990;12:1179–86.
Jego TG, Bataille RG, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood. 2001;97:1817–22.
Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: Recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53:2143–54.
Lazzerini PE, Acampa M, Cupelli M, et al. Unravelling atrioventricular block risk in inflammatory diseases: Systemic inflammation acutely delays atrioventricular conduction via a cytokine-mediated inhibition of connexin43 expression. J Am Heart Assoc. 2021;10:e022095.
Baek HJ, Lim MJ, Park W, et al. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. Korean J Intern Med. 2019;34:917–31.
Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: An evidence-based review and patient selection. Drug Des Devel Ther. 2019;13:57–70.
Scott LJ. Tocilizumab: A review in rheumatoid arthritis. Drugs. 2017;77:1865–79.
Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17.
Rao VU, Pavlov A, Klearman M, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015;67:372–80.
Castagné B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One. 2019;14.
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97.
Lazzerini PE, Acampa M, Capecchi PL, et al. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: Tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res (Hoboken). 2015;67:332–9.
Khader Y, Beran A, Ghazaleh S, Lee-Smith W, Altorok N. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022;41:3615–27.
Wang J, Devenport J, Low JM, Yu D, Hitraya E. Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to Tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:882–5.
Hussain A, Tarahomi T, Singh L, Bollampally M, Heydari-Kamjani M, Kesselman MM. Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis. Cureus. 2021;13:e17938.
Sinagra E, Perricone G, Romano C, Cottone M. Heart failure and anti-tumor necrosis factor-alpha in systemic chronic inflammatory diseases. Eur J Intern Med. 2013;24:385–92.
Anand CP, Al-Juburi A, Sandeep B. Heart block occurring during infliximab therapy: a report of two cases. Am J Gastroenterol Suppl. 2003;98:S144.
Siebert S, Amos N, Lawson TM. Complete heart block after infliximab therapy. Rheumatology. 2008;47:228–9.
Lee H, Lee S Il, Kim HO. Recent advances in basic and clinical aspects of rheumatoid arthritis-associated interstitial lung diseases. J Rheum Dis. 2022;29:61–70.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Christian Johan, Fatih Anfasa, Adityo Susilo, Johanda Damanik, Rudy Hidayat, Sumariyono Sumariyono, RM. Suryo Anggoro Kusumo Wibowo, Anna Ariane, Faisal Parlindungan, Abirianty Priandani Araminta
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
